Freddy T. Nguyen, MD, PhD

Freddy T. Nguyen is a physician-scientist, entrepreneur, and healthcare innovator with a strong focus on developing and translating biomedical optical technologies and nanotechnologies. His work aims to advance functional precision medicine by enabling faster and more dynamic diagnostic information, particularly for selecting effective cancer treatments. freddynguyen+1

As CEO and Co-Founder of Nine Diagnostics, Freddy Nguyen is leading a company focused on AI-enabled nanosensor technology for early disease detection and treatment monitoring. His leadership at Nine Diagnostics has been recognized with significant achievements such as selection for Merck Digital Sciences Studio and a Novo Nordisk Golden Ticket. freddynguyen+1

Nguyen is a dedicated advocate for physician-scientist trainees, having founded, presided over, and chaired the American Physician Scientists Association (APSA). Under his leadership, APSA grew significantly, providing a platform for mentorship, networking, and advocacy within the physician-scientist community, and earning him recognition including the AMA Foundation's Excellence in Medicine Award. freddynguyen+1

His postdoctoral research at MIT, supported by an Arnold O. Beckman Postdoctoral Fellowship, involved developing innovative nanoscale sensors for molecular recognition of chemotherapeutic drugs and cell death markers. This work focused on evaluating drug delivery and cancer therapy effectiveness using optical technologies, hydrogel chemistry, and nanotechnology. beckman-foundation+2

Freddy Nguyen has played a pivotal role in healthcare innovation ecosystems, co-directing MIT Hacking Medicine and co-founding/co-directing both the MIT COVID-19 Challenge and the MIT Hacking Racism Challenge. These initiatives demonstrate his commitment to fostering innovation and addressing critical issues in healthcare and health equity. freddynguyen

His academic background includes an MD from the University of Illinois College of Medicine and a PhD in Chemistry from the University of Illinois at Urbana-Champaign, where his doctoral research focused on Optical Coherence Tomography (OCT) for intraoperative breast cancer margin assessment and targeted multimodal protein microspheres for imaging. freddynguyen+1